Sign in Subscribe

Alex Chompff

Fear of recurrence and coping strategies in CRC survivors

Skip to content The CRC Digest Fear of recurrence and coping strategies in CRC survivors A pilot mixed-methods study quantified fear of cancer recurrence using the FCRI Short Form and examined associations with Brief COPE coping domains in 23 patients who underwent CRC surgery. (HCA Healthc J Med) This content

Quality of life and physical function after metastasis treatment in older patients

Skip to content The CRC Digest Quality of life and physical function after metastasis treatment in older patients A Dutch cohort study evaluated long-term quality of life and physical functioning in patients aged ≥70 years with metastatic colorectal cancer treated with curative local surgical or ablative therapy. (Eur J Surg

Rural and Appalachian communities face geographic barriers to colonoscopy access

Skip to content The CRC Digest ▪ SCREENING Rural and Appalachian communities face geographic barriers to colonoscopy access A national geospatial analysis of all contiguous US census tracts quantified colonoscopy provider access and screening prevalence, comparing rural-urban and Appalachian-non-Appalachian regions where CRC incidence and mortality are disproportionately high. (Prev Chronic Dis)

Chemoradiotherapy plus immunotherapy may expand checkpoint blockade benefit in mismatch repair-proficient rectal cancer

Skip to content The CRC Digest ◇ RESEARCH Chemoradiotherapy plus immunotherapy may expand checkpoint blockade benefit in mismatch repair-proficient rectal cancer Adding immune checkpoint blockade to chemoradiotherapy has been associated with pathological complete response rates of 30% or more in pMMR rectal cancer trials, higher than expected with chemoradiotherapy alone, though

Fatigue remains common five years after rectal cancer treatment

Skip to content The CRC Digest ♥ LIVING WITH CRC Fatigue remains common five years after rectal cancer treatment The QoLiRECT study investigated fatigue prevalence at 5 years after rectal cancer surgery using the Piper Fatigue Scale, examining baseline characteristics and treatment-related factors as potential predictors of moderate-severe fatigue. (Acta Oncol)

Five-year colonoscopy surveillance may be as safe as three-year intervals after high-risk polyp removal

Skip to content The CRC Digest ▪ SCREENING Five-year colonoscopy surveillance may be as safe as three-year intervals after high-risk polyp removal A European randomized trial compared colonoscopy at 5 years versus 3 years after removal of high-risk adenomas (≥10 mm, high-grade dysplasia, villous features, or 3–10 adenomas), with 10-year

CRC Research Update — September 16, 2026

Today's colorectal cancer research highlights

Critical review outlines biomarker-guided treatment selection in metastatic CRC

Skip to content The CRC Digest Critical review outlines biomarker-guided treatment selection in metastatic CRC A structured narrative review separately examines mismatch repair-deficient/MSI-H and microsatellite-stable disease, distinguishing established treatments from investigational strategies based on molecular alterations including BRAF V600E and HER2. (Crit Rev Oncol Hematol) This content is informational

Prospective study examines MSI and CD8+ TILs in neoadjuvant chemotherapy response

Skip to content The CRC Digest Prospective study examines MSI and CD8+ TILs in neoadjuvant chemotherapy response A prospective observational study investigated whether microsatellite instability, CD8+ tumor infiltrating lymphocytes expression, and chemotherapy response are related in colorectal cancer patients receiving neoadjuvant treatment. (Cancer Manag Res) This content is informational only

Oral KRAS G12D inhibitor GFH375 evaluated in phase 1 trial

Skip to content The CRC Digest Oral KRAS G12D inhibitor GFH375 evaluated in phase 1 trial GFH375 targets both GTP-bound and GDP-bound states of KRAS G12D proteins, the most prevalent RAS mutation in solid tumors, in patients with advanced colorectal cancer, pancreatic cancer, and non-small cell lung cancer. (Nat Med)